Switch theme
Sign up to access all valuation multiples
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
2016
800
LTM Revenue $63.5M
LTM EBITDA -$475M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Recursion Pharmaceuticals has a last 12-month revenue (LTM) of $63.5M and a last 12-month EBITDA of -$475M.
In the most recent fiscal year, Recursion Pharmaceuticals achieved revenue of $58.5M and an EBITDA of -$427M.
Recursion Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Recursion Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $63.5M | XXX | $58.5M | XXX | XXX | XXX |
| Gross Profit | $6.2M | XXX | $13.3M | XXX | XXX | XXX |
| Gross Margin | 10% | XXX | 23% | XXX | XXX | XXX |
| EBITDA | -$475M | XXX | -$427M | XXX | XXX | XXX |
| EBITDA Margin | -748% | XXX | -730% | XXX | XXX | XXX |
| EBIT | -$508M | XXX | -$479M | XXX | XXX | XXX |
| EBIT Margin | -799% | XXX | -819% | XXX | XXX | XXX |
| Net Profit | -$508M | XXX | -$464M | XXX | XXX | XXX |
| Net Margin | -799% | XXX | -793% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Recursion Pharmaceuticals's stock price is $4.
Recursion Pharmaceuticals has current market cap of $1.7B, and EV of $1.3B.
See Recursion Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.7B | XXX | XXX | XXX | XXX | $-1.58 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Recursion Pharmaceuticals has market cap of $1.7B and EV of $1.3B.
Recursion Pharmaceuticals's trades at 22.1x EV/Revenue multiple, and -3.0x EV/EBITDA.
Equity research analysts estimate Recursion Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Recursion Pharmaceuticals has a P/E ratio of -3.3x.
See valuation multiples for Recursion Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 20.3x | XXX | 22.1x | XXX | XXX | XXX |
| EV/EBITDA | -2.7x | XXX | -3.0x | XXX | XXX | XXX |
| EV/EBIT | -2.5x | XXX | -2.7x | XXX | XXX | XXX |
| EV/Gross Profit | 209.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.3x | XXX | -3.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRecursion Pharmaceuticals's last 12 month revenue growth is 30%
Recursion Pharmaceuticals's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.6M for the same period.
Recursion Pharmaceuticals's rule of 40 is -671% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Recursion Pharmaceuticals's rule of X is -674% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Recursion Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 30% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Margin | -748% | XXX | -730% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -671% | XXX | -700% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -674% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 538% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 842% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Recursion Pharmaceuticals acquired XXX companies to date.
Last acquisition by Recursion Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Recursion Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Recursion Pharmaceuticals founded? | Recursion Pharmaceuticals was founded in 2016. |
| Where is Recursion Pharmaceuticals headquartered? | Recursion Pharmaceuticals is headquartered in United States of America. |
| How many employees does Recursion Pharmaceuticals have? | As of today, Recursion Pharmaceuticals has 800 employees. |
| Who is the CEO of Recursion Pharmaceuticals? | Recursion Pharmaceuticals's CEO is Dr. Christopher Gibson, PhD. |
| Is Recursion Pharmaceuticals publicy listed? | Yes, Recursion Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Recursion Pharmaceuticals? | Recursion Pharmaceuticals trades under RXRX ticker. |
| When did Recursion Pharmaceuticals go public? | Recursion Pharmaceuticals went public in 2021. |
| Who are competitors of Recursion Pharmaceuticals? | Similar companies to Recursion Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Recursion Pharmaceuticals? | Recursion Pharmaceuticals's current market cap is $1.7B |
| What is the current revenue of Recursion Pharmaceuticals? | Recursion Pharmaceuticals's last 12 months revenue is $63.5M. |
| What is the current revenue growth of Recursion Pharmaceuticals? | Recursion Pharmaceuticals revenue growth (NTM/LTM) is 30%. |
| What is the current EV/Revenue multiple of Recursion Pharmaceuticals? | Current revenue multiple of Recursion Pharmaceuticals is 20.3x. |
| Is Recursion Pharmaceuticals profitable? | Yes, Recursion Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Recursion Pharmaceuticals? | Recursion Pharmaceuticals's last 12 months EBITDA is -$475M. |
| What is Recursion Pharmaceuticals's EBITDA margin? | Recursion Pharmaceuticals's last 12 months EBITDA margin is -748%. |
| What is the current EV/EBITDA multiple of Recursion Pharmaceuticals? | Current EBITDA multiple of Recursion Pharmaceuticals is -2.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
